Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All patients must be able to give informed consent.~The definition of severe asthma will be on the basis of:~1. Treatment: High dose of ICS ± OCS ≥ 1000mcg FP daily or equivalent plus one other controller medication.~2. Disease Control: Uncontrolled (GINA guidelines), three or more of the following present in any week in the preceding 4 weeks:~   1. Daytime symptoms more than twice per week~  2. Any limitation of activities~  3. Nocturnal symptoms once or more per week~  4. Need for reliever treatment more than twice per week~  5. Prebronchodilator FEV1 \<80% predicted or personal best AND/OR Frequent severe exacerbations (≥2 per year requiring high dose OCS or doubling of maintenance dose for at least three days or requiring hospitalisation).~3. Asthma Diagnosis:~Improvement in FEV1 ≥ 12% or 200ml predicted after inhalation of 400mcg salbutamol OR Diurnal variation in PEF: amplitude % mean of twice daily PEF \> 8% OR Decrease in FEV1 ≥ 12% and \>200ml within 4 weeks after tapering treatment with one or more of the following drugs: ICS, OCS, LABA, SABA PLUS A history of wheeze occurring spontaneously or on exertion.~Exclusion Criteria:~1. Patients with a FEV1 \< 1L~2. Any other active lung condition~3. Subjects unable to give consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Astma patients (Type: EXPERIMENTAL): Participant undergoes a bronchoscopy to isolate epithelial cells

Based on this trial design, predict the completion outcome and termination type (if applicable).